HRHans Rickli

Hans Rickli

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hans Rickli has a total of 104 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Sex differences in prescription patterns of secondary prevention pharmacotherapy in patients with acute myocardial infarction: a 20-year insight from the AMIS Plus registry

    by Lara Berther, Dragana Radovanovic, Marco Roffi, Barbara Stähli, Giovanni Pedrazzini, Hans Rickli, on behalf of the AMIS Plus investigators

    AIMS: Recent studies have demonstrated sex-related differences in secondary prevention pharmacotherapy in patients with acute myocardial infarction, although guidelines recommend the same preventive approach in both women and men. This study builds upon previous research by examining temporal trends in prescribing patterns of secondary prevention medications using contemporary, long-term data from Switzerland, with particular focus on sex-related disparities. METHODS: Acute myocardial infarction patients enrolled in the AMIS (Acute Myocardial Infarction in Switzerland) Plus project between 2003 and 2022 were included. For this retrospective analysis, optimal medical therapy was defined as the combination of all five guideline-recommended medications at discharge: aspirin; P2Y12 inhibitor; lipid-lowering drug; beta-blocker; angiotensin-converting enzyme inhibitor or angiotensin receptor blocker. Uni- and multivariable logistic regression analyses were performed. RESULTS: Among 34,612 patients (75% men, n=25,913), women were older and had more comorbidities but were less frequently prescribed optimal medical therapy than men (51% vs 60%) across all age groups (all p <0.001), with the greatest gap occurring in patients <50 years of age. A marked increase in optimal medical therapy prescription (36% to 60%) was detected irrespective of age and sex, mainly due to greater prescription of dual antiplatelet therapy (71% to 91%) and lipid-lowering drugs (69% to 93%). The sex-related gap in optimal medical therapy prescription disfavouring women showed a fluctuating trend (0.7–14%) whereas there was a progressive and sustained reduction regarding the combination of dual antiplatelet therapy plus lipid-lowering drug, from 18% to 10% at the beginning and the end of the observation period, respectively. Multivariable analysis showed greater frequency of optimal medical therapy prescription in patients with STEMI (OR: 1.65, 95% CI: 1.57–1.73) and those treated with PCI (OR: 4.85, 95% CI: 4.49–5.24), whereas lower prescription frequencies were observed among female patients (OR: 0.90, 95% CI: 0.85–0.95) and older individuals (OR per additional year: 0.99, 95% CI: 0.98–0.99). CONCLUSIONS: Although optimal medical therapy prescription increased gradually over time among both women and men, concerning sex disparities disfavouring women, particularly young women, remained. Targeted programmes to reduce sex-related differences in secondary prevention care are warranted.

  • Open Access

    The impact of basic vs private health insurance status on treatments and outcomes of ST-elevation myocardial infarction patients in Switzerland: insights from the AMIS Plus registry

    by Jan Loosli, Fabienne Foster-Witassek, Marco Roffi, Viktor von Wyl, Hans Rickli, Giovanni Pedrazzini, Dragana Radovanovic

    BACKGROUND: Large disparities in treatments and outcomes of ST-elevation myocardial infarction (STEMI) patients driven by insurance status have been reported. However, it is unknown whether this applies to Switzerland, a country characterised by an overall high income, mandatory basic health insurance covering virtually all treatments and the option of a supplementary private health insurance allowing for full institution and doctor choice as well as a higher service standard. This study aimed to assess the impact of insurance status on treatments and outcomes in STEMI patients in Switzerland. METHODS: STEMI patients enrolled in the nationwide Acute Myocardial Infarction in Switzerland (AMIS) Plus registry between 2005 and 2023 were analysed. We compared patients with basic health insurance only to those with supplementary private health insurance with respect to optimal medical therapy, percutaneous coronary intervention (PCI) and outcomes. Primary outcome measures were rates of optimal medical therapy and full guideline-recommended treatment (FGRT) (defined as optimal medical therapy plus PCI). Secondary outcome measures were in-hospital all-cause mortality, major adverse cardiac and cerebrovascular events (MACCE), length of stay and 1-year all-cause mortality after discharge. Multivariate logistic mixed-effects models examined whether insurance type influenced treatments and outcomes. RESULTS: Among 16,463 patients, 13,023 (79.1%) had only basic health insurance. Patients with basic health insurance only were younger, more often males and had higher rates of obesity, diabetes and active smoking, but lower rates of cancer than supplementary private health insurance patients. In addition, they more often received optimal medical therapy and FGRT. Patients with basic health insurance only had higher rates of in-hospital mortality and MACCE. However, after adjusting for covariates, no statistically significant associations were identified between insurance type and access to optimal medical therapy or FGRT, in-hospital mortality, MACCE, length of stay or 1-year mortality after discharge. CONCLUSION: In this study, we observed no significant association between insurance status and treatments or outcomes of STEMI patients, suggesting a high level of equity in acute cardiac care in Switzerland.

  • Impact of high-grade atrioventricular block on outcomes in patients with acute myocardial infarction

    by Nicola Olivito, Fabienne Foster Witassek, Hans Rickli, Marco Roffi, Dragana Radovanovic, Giovanni Pedrazzini

    Aims: Contemporary data on the impact of high-grade atrioventricular blocks (HAVB) in acute myocardial infarction (AMI) are scarce. Therefore, we investigated this in the Swiss national AMI registry (AMIS Plus) cohort. Methods and results: We included all AMI patients enrolled from January 2005 to September 2024 with available ECG information. Primary outcome was in-hospital mortality; secondary outcomes included in-hospital major adverse cardiac or cerebrovascular events (MACCE) defined as cardiogenic shock, stroke, re-infarction or death. Among 50 279 AMI patients, 747 (1.5%) patients presented with HAVB and 407 (0.8%) developed HAVB during hospitalization. Patients presenting with HAVB had increased in-hospital mortality (15% vs. 4.9%; P < 0.001) and MACCE (17% vs. 6.0%; P < 0.001) compared with those without HAVB. High-grade atrioventricular blocks on admission was an independent predictor for in-hospital mortality (OR 1.89; 95% CI, 1.42–2.49; P < 0.001), with a stronger impact on mortality in the setting of anterior compared to non-anterior AMI (OR 3.69; 95% CI, 1.99–6.81; pinteraction = 0.02). Independent predictors for HAVB on admission included STEMI and female sex. Rates of permanent pacemaker implantation during hospitalization in patients with HAVB on admission were higher in NSTEMI than STEMI patients (20% vs. 4.4%; P < 0.001). High-grade atrioventricular blocks occurring during hospital stay was associated with higher mortality (20% vs. 15%; P = 0.031) and higher permanent pacemaker rate (25% vs. 8%; P < 0.001) than HAVB on admission. Conclusion: High-grade atrioventricular blocks in AMI was associated with high in-hospital mortality, especially in anterior AMI or if occurring during hospitalization. Permanent pacemaker implantation was more frequent in the setting of NSTEMI and among patients developing HAVB during hospital stay.


  • Open Access

    Sex-specific prediction of cardiogenic shock after acute coronary syndromes: the SEX-SHOCK score

    by Yifan Wang, Marianne Zeller, Vincent Auffret, Georgios Georgiopoulos, Lorenz Räber, Marco Roffi, Christian Templin, Olivier Muller, Luca Liberale, Stefano Ministrini, et al.

    And aims: Cardiogenic shock (CS) remains the primary cause of in-hospital death after acute coronary syndromes (ACS), with its plateauing mortality rates approaching 50%. To test novel interventions, personalized risk prediction is essential. The ORBI (Observatoire Régional Breton sur l’Infarctus) score represents the first-of-its-kind risk score to predict in-hospital CS in ACS patients undergoing percutaneous coronary intervention (PCI). However, its sex-specific performance remains unknown, and refined risk prediction strategies are warranted. This multinational study included a total of 53 537 ACS patients without CS on admission undergoing PCI. Following sex-specific evaluation of ORBI, regression and machine-learning models were used for variable selection and risk prediction. By combining best-performing models with highest-ranked predictors, SEX-SHOCK was developed, and internally and externally validated. The ORBI score showed lower discriminative performance for the prediction of CS in females than males in Swiss (AUC [95% CI]: 0.78 [0.76-0.81] vs. 0.81 [0.79-0.83]; p=0.048) and French ACS patients (0.77 [0.74-0.81] vs. 0.84 [0.81-0.86]; p=0.002). The newly developed SEX-SHOCK score, now incorporating ST-segment elevation, creatinine, C-reactive protein, and left ventricular ejection fraction, outperformed ORBI in both sexes (females: 0.81 [0.78-0.83]; males: 0.83 [0.82-0.85]; p<0.001), which prevailed following internal and external validation in RICO (females: 0.82 [0.79-0.85]; males: 0.88 [0.86-0.89]; p<0.001) and SPUM-ACS (females: 0.83 [0.77-0.90], p=0.004; males: 0.83 [0.80-0.87], p=0.001). The ORBI score showed modest sex-specific performance. The novel SEX-SHOCK score provides superior performance in females and males across the entire spectrum of ACS, thus providing a basis for future interventional trials and contemporary ACS management.


  • Open Access

    Nachruf – Professor Paul J. E. Erne

    by Thomas Lüscher, Hans Rickli, Michel Zuber

  • Open Access

    Obituary—Professor Paul J. E. Erne

    by Thomas F Lüscher, Hans Rickli, Michel Zuber


  • Valor pronóstico de las frecuencias cardiacas bajas en pacientes ingresados con infarto agudo de miocardio

    by Luigi Biasco, Fabienne Foster-Witassek, Dragana Radovanovic, Philip Dittli, Gregorio Tersalvi, Hans Rickli, Marco Roffi, Franz Eberli, Raban Jeger, Paul Erne, et al.

  • Open Access

    Sex differences in acute coronary syndromes: a never ending same old story or sign for improvement

    by D Radovanovic, R Schoenenberger-Berzins, M Roffi, G Pedrazzini, F Eberli, P Erne, H Rickli

    Introduction: We previously described sex differences in baseline characteristics, interventional therapy and mortality in patients admitted for acute coronary syndromes (ASC) in Swiss hospitals and enrolled in the AMIS Plus registry between 1997 and 2006 (1). This present analysis aimed to reassess whether anything changed over the last 15 years. Method: All AMIS Plus patients enrolled between 2007 and 2021 were included. Baseline characteristics, therapy and outcome were analysed according to sex and age groups. Multivariate analyses were performed to assess independent predictors of in-hospital mortality. Results: Among 42,471 patients, 10,825 (25.5%) were women. Women were still older (71.6±12.6y vs. 64.2±12.6y for men), had more comorbidities (Charlson Comorbidity Index>1: 26.5% vs. 21.7%), were less likely to receive drug therapy (e.g., P2Y12 inhibitors 83.3% vs. 89.2% or statins 73.0% vs. 78.5%) and underwent percutaneous coronary intervention (PCI) less frequently (OR 0.77; 95% CI 0.73–0.83). These findings paralleled our observations for the period 1997–2006. However, the increase in PCI use over the years, particularly in women, led to a marked decrease in differences between men and women with respect to revascularization, from 16.6% in 2006 down to 2.0% in 2020. Unadjusted in-hospital mortality was higher in women (OR 1.55; 95% CI 1.41–1.70), but this significance disappeared after adjustment for baseline differences (OR 1.07; (95% CI 0.96–1.20)). However, in women under the age of 50 years, crude mortality (3.1% versus 1.6%) was significantly higher than in same-aged men; adjusted OR 1.78 (95% CI 0.99–3.20). Conclusions: Sex differences in the baseline characteristics of ACS patients and the use of evidence-based drugs persisted but the sex gap in PCI access slowly but surely diminished. Female sex per se was not an independent predictor of in-hospital mortality in the overall population but it showed a strong trend among patients younger than 50 years of age. Funding Acknowledgement: Type of funding sources: None.

  • Open Access

    Treatment and outcome of patients with acute myocardial infarction and chronic lung disease: insights from the nationwide AMIS Plus registry

    by C Beckmann, F Foster-Witassek, M Brutsche, M T Maeder, F Eberli, M Roffi, G Pedrazzini, D Radovanovic, H Rickli

    Introduction: Little is known about patients with acute myocardial infarction (AMI) and chronic lung disease (CLD). The aim of our study was to analyze risk factors, treatment, and outcome of AMI patients with CLD over the last 20 years using the nationwide AMIS Plus registry. Methods: All AMI patients enrolled in the AMIS Plus registry with data on CLD between January 2002 and December 2021 were included. Chronic lung disease was determined according to the definition used in the Charlson Comorbidity Index. Data on baseline characteristics, regular medication, immediate therapy within 24 hours, in-hospital interventions and treatments, in-hospital outcome, complications and discharge medication were analyzed using descriptive statistics and logistic regression. Results: Among 53,680 AMI patients, 5.8% had a CLD. The CLD group included 26.6% female and 73.4% male patients. Gender distribution was similar in patients with and without CLD. Patients with CLD were significantly older (71.2 vs. 65.8 y; p<0.001), more frequently diagnosed with NSTEMI, had more comorbidities and were less frequently never smokers (17.4% vs. 35.3%; p<0.001) compared to patients without CLD. In addition, CLD patients were less likely to receive aspirin, P2Y12 inhibitors, beta-blockers, ACE inhibitors and statins (all p<0.001), and were also less likely to undergo percutaneous coronary interventions (68.7% vs. 82.5%; p<0.001). Median length of stay was 2 days longer for CLD patients. Patients with CLD had more major adverse cardiac and cerebrovascular events in-hospital (10.3% vs. 5.9%; p<0.001) and higher crude in-hospital mortality (8.3% vs. 4.7%; p<0.001). However, multivariable regression analysis showed that CLD was not an independent predictor for in-hospital mortality (OR 1.19 (95% CI 0.98–1.45), p=0.081). Conclusion: Patients with CLD were less likely to receive evidence-based medicine and had a worse in-hospital outcome compared to those without CLD. However, after adjustment, CLD was not an independent predictor of in-hospital mortality. Funding Acknowledgement: Type of funding sources: Private company. Main funding source(s): AstraZeneca AG, Biotronik (Schweiz) AG

  • Open Access

    Bleeding risk in patients hospitalized for non-ST-segment elevation acute coronary syndromes in Switzerland: performance of the CRUSADE score

    by F Wenzl, S Kraler, L Raeber, B E Staehli, M Roffi, O Muller, N Rodondi, G G Camici, M A Puhan, H Rickli, et al.

    Background: Evaluation of bleeding risk is critical to the management of patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS). The CRUSADE score is the most established tool to estimate major bleeding events following the index NSTE-ACS. Purpose: We aimed to assess the performance of the CRUSADE score and the predictive utility of the individual score variables in contemporary European populations. Methods: The CRUSADE score was studied in prospectively recruited Swiss patients with NSTE-ACS included in the multicentre SPUM-ACS study (n=4'787) and main findings were validated in the nation-wide AMIS Plus registry (n=46'939). Major bleeding during hospitalization was defined as Bleeding Academic Research Consortium (BARC) class IIIB, IIIC, IV, or V. Discrimination was evaluated by the area under the receiver operating characteristic curve (AUC). Multivariable-adjusted risk ratios (adj RR) were estimated for each of the 8 score variables. Hematocrit estimates were based on hemoglobin concentrations in AMIS Plus. Analyses were performed on complete and imputed data (multiple imputation using chained equations). Results: CRUSADE showed poor discriminatory performance (SPUM-ACS: AUC, 0.65; 95% CI 0.57 to 0.72) and low balanced accuracy (SPUM-ACS: 0.50). Risk predicted by CRUSADE exceeded the observed risk across all predefined risk categories (very low, low, moderate, high, and very high). Decision curve analyses suggested little to no net benefit from using the score. Adjusting for other score variables, signs of heart failure (adj RR, 3.83; 95% CI, 1.93 to 7.37), low hematocrit (adj RR, 2.16; 95% CI, 0.55 to 7.70; 40%), and low systolic blood pressure (adj RR, 2.70; 95% CI, 1.14 to 6.16; 121 mmHg) were the strongest predictors of major in-hospital bleeds in SPUM-ACS. These findings were similarly observed in AMIS Plus. Conclusion: The CRUSADE score overestimates bleeding risk in NSTE-ACS. Among all 8 score variables, signs of heart failure, low hematocrit, and low systolic blood pressure are the strongest predictors of major in-hospital bleeds in contemporary patients with NSTE-ACS. Funding Acknowledgement: Type of funding sources: Public Institution(s). Main funding source(s): Swiss National Science FoundationSwiss Heart Foundation